An initiative of IBA Proton Therapy
Campus your proton
therapy community
  • Resource center
  • Training
  • Events
  • About
  • Log in
  • Resource center
  • Training
  • Events
  • About
  • Log in
An initiative of IBA Proton Therapy

Your results for

Filter by

Filter by
Results

Filter by

Content type
  • Event - Do not use (0)
  • Podcast (0)
  • Publications (235)
  • Training (0)
  • User case (4)
  • User meeting (1)
  • Webinar (13)
  • White paper (2)
Key content topics
Key audience
  • Newcomers (0)
Top cancer treatments
  • Brain and CNS (88)
  • Breast (59)
  • (-) Gastro-intestinal (125)
  • Genito-urinary (51)
  • Gynecological (7)
  • (-) Head and neck (133)
  • Hodgkin and Non-Hodgkin lymphoma (16)
  • Ocular (12)
  • Pediatric (100)
  • Reirradiation (12)
  • Sarcomas (18)
  • Thoracic (91)
  • Reset filters
  • (-) Gastro-intestinal
  • (-) Head and neck

Hypofractionated proton beam radiotherapy in patients with unresectable liver tumors: multi-institutional prospective results from the Proton Collaborative Group.

10/11/2020
/ Publications
/
Hypofractionation

This study analyzed the data of 63 patients with liver tumors treated with PBT. Hypofractionated PBT resulted in excellent local control, sparing of the...

Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: a randomized phase trial.

01/10/2020
/ Publications
/
Toxicity

This randomized study compared PBT and radiofrequency ablation (RFA) for patients with recurrent/residual HCC. The local progression free survival values of PBT...

Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable HCC Treated with Radiotherapy.

04/03/2021
/ Publications

Lymphopenia caused by radiotherapy is associated with a poor prognosis. This study reviewed 143 HCC patients treated with photon (n=103 (72%)) and proton (n=40...

Abscopal Effect Followiing PBRT in a Patient With Inoperable Metastatic Retroperitoneal Sarcoma.

09/09/2019
/ Publications
/
Immunotherapy

The first case report of an abscopal effect in a patient of retroperitoneal sarcomas (RPS) treated with proton therapy. A 67 year-old female with inoperable...

Patterns of failure and toxicity profile following proton beam therapy for pediatric bladder and prostate rhabdomyosarcoma (B/P-RMS).

07/08/2019
/ Publications
/
Toxicity

This study reported outcomes of 19 patients of B/P-RMS treated with PBT. With a median follow-up of 66.2 months, 5-year overall survival (OS) and progression...

Optimizing neoadjuvant radiotherapy for resectable and borderline resectable pancreatic cancer using protons.

07/07/2019
/ Publications

Approximately 25% of patients diagnosed with pancreatic cancer present with non-metastatic resectable or borderline resectable disease. Preoperative...

Proton beam therapy versus stereotactic body radiotherapy for hepatocellular carcinoma: practice patterns, outcomes, and the effect of biologically effective dose escalation.

07/10/2019
/ Publications

With the National Cancer Database for T1-2N0 HCC patients receiving PBT or SBRT, a total of 71 patients received PBT and 918 patients received SBRT were...

A comparison of the outcomes between surgical resection and proton beam therapy for single primary hepatocellular carcinoma.

07/10/2019
/ Publications

There were 314 and 31 patients with single primary nodular HCC ≤ 100 mm without vessel invasion who underwent surgical resection (SR) and PBT were analyzed. The...

Protons versus Photons for Unresectable Hepatocellular Carcinoma: Liver Decompensation and Overall Survival.

07/01/2019
/ Publications

Published in the Red Journal, this single-institution retrospective study compared clinical outcomes of proton versus photon ablative radiation therapy in...

Extreme hypofractionated proton radiotherapy for prostate cancer using pencil beam scanning: Dosimetry, acute toxicity and preliminary results.

07/09/2019
/ Publications
/
Hypofractionation
Pencil Beam Scanning - PBS

A study by the research group in Prague. Two hundred patients with early-stage prostate cancer were treated with IMPT on extreme hypofractionated schedule (36...

Pagination

  • Previous page ‹
    • Page 17
    • Current page 18
    • Page 19
  • Next page ›
Campus
Subscribe to our newsletter
Follow us on
  • Facebook
  • Linkedin
  • Twitter
  • Youtube
Contact us
  • About Campus
  • Resources
  • Training
  • Connect
  • IBA Worldwide
  • Back to IBA Proton Therapy
Life Science
  • Legal
  • Terms of Use
  • Privacy policy
  • Cookies policy
  • Manage cookies
  • Code of conduct

Cookies policy

If you continue browsing this website, you agree to the use of cookies in order to provide you with services and offers tailored to your own interests.

Manage your cookie preferences

Respect for your privacy is still a priority for us at IBA.

Functional cookies ensure that the website runs smoothly. They cannot be turned off. By setting your preferences, you can turn the use of these cookies on and off on our website, although these settings will only be valid on the device you are currently using.

Accept all cookies
Adapt my preferences
Cookies policies